Minimally invasive laparoscopic treatment for gastric cancer with sigmoid colon cancer: a report of 1 case_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YU Hualong ,  WANG Xixun ,  JIANG Lixin

The First Department of Gastrointestinal Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P. R. China;

Corresponding?author：

WANG Xixun, Email: w70063@sina.com; JIANG Lixin, Email: jianglixin1969@hotmail.com

Keywords：

multiple primary cancer; gastric cancer; colon cancer; laparoscopic surgery

DOI：

10.7507/1007-9424.201907049

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the diagnosis and treatment of a primary gastric colon cancer, and to explore its safety and feasibility.Method The clinical data of a patient with gastric cancer and sigmoid colon cancer who admitted to The Affiliated Yantai Yuding Hospital of Qingdao University in October 2017 was analyzed.Results The patient underwent laparoscopic radical gastrectomy plus π anastomosis and laparoscopic radical resection of colon cancer. The operation time was 330 min and the intraoperative blood loss was 120 mL. There were no complications such as stomach cramps and sputum after operation and he was successfully discharged on the 9^th day after surgery. Postoperative pathological staging: gastric cancer (pT3N3M0, ⅢB) and sigmoid colon cancer (pT2N0M0, Ⅰ B).Conclusions Multiple primary cancer of the simultaneous gastric colon should be diagnosed before operation. Laparoscopic minimally invasive treatment for gastric cancer with sigmoid colon cancer is safe and feasible, and can benefit patients.

Citation： YU Hualong, WANG Xixun, JIANG Lixin. Minimally invasive laparoscopic treatment for gastric cancer with sigmoid colon cancer: a report of 1 case. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(10): 1217-1221. doi: 10.7507/1007-9424.201907049 Copy

1.	陳學燕, 李利亞. 多原發惡性腫瘤臨床特點及發病機制的研究進展. 中日友好醫院學報, 2019, 33(1): 41-44.
2.	Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst, 2007, 99(21): 1634-1643.
3.	Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
4.	Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet, 2013, 50(4): 255-263.
5.	Molina-Montes E, Requena M, Sánchez-Cantalejo E, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol, 2015, 136(1): 158-171.
6.	Lenters-Westra E, Slingerland RJ. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin Chem, 2014, 60(8): 1062-1072.
7.	Braisch U, Meyer M, Radespiel-Tr?ger M. Risk of tobacco-related multiple primary cancers in Bavaria, Germany. BMC Cancer, 2012, 12: 250.
8.	奧婷, 孫軍平, 張明月, 等. 肺癌合并其他原發惡性腫瘤 55 例發病特點分析. 解放軍醫學院學報, 2016, 37(3): 226-228, 241.
9.	Utada M, Ohno Y, Hori M, et al. Incidence of multiple primary cancers and interval between first and second primary cancers. Cancer Sci, 2014, 105(7): 890-896.
10.	宋詩平, 趙越, 王春玉. 雌激素受體在甲狀腺癌中作用的研究進展. 生命科學, 2017, 29(5): 489-494.
11.	Noguchi M, Naruki Y, Matsuo K, et al. A case report of triple malignant tumor including early gastric carcinoma–multiple primary malignant tumors, a survey of the literatures and a statistical study (author’s transl). Nihon Shokakibyo Gakkai Zasshi, 1978, 75(1): 71-79.
12.	Jin B, Zhang S, Chuang X, et al. Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report. BMC Cancer, 2018, 18(1): 1138.
13.	蘭春斌, 賈貴清, 袁浩, 等. 新輔助化療聯合完全腹腔鏡下遠端胃癌 D2 根治術的臨床療效. 中國臨床研究, 2019, 32(6): 747-750, 754.
14.	Shoji F, Yamazaki K, Miura N, et al. Postoperative management of multiple primary cancers associated with non-small cell lung cancer. Anticancer Res, 2018, 38(6): 3773-3778.
15.	Baba Y, Yoshida N, Kinoshita K, et al. Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: a retrospective single-institution study. Ann Surg, 2018, 267(3): 478-483.
16.	郭銳, 李囡, 王菲, 等. ¹⁸F-FDG PET/CT 在同時性多原發癌中的應用. 腫瘤, 2018, 38(4): 371-378.
17.	徐玲玲, 顧康生. 170 例多原發惡性腫瘤的臨床分析. 安徽醫科大學學報, 2011, 46(12): 1318-1321.
18.	端木媛媛, 王瑞平. 王瑞平教授治療多原發癌的經驗. 中醫藥導報, 2018, 24(9): 53-54, 65.
19.	孫俊杰, 李雙慶. 多原發癌病因及發病機制的探索. 中國全科醫學, 2017, 20(9): 1136-1141.
20.	Gustafsson UO, Scott MJ, Schwenk W, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(?)) Society recommendations. World J Surg, 2013, 37(2): 259-284.
21.	韓偉峰, 費伯健, 高其忠, 等. ERAS 用于進展期胃癌 D2 根治術對胃腸功能恢復情況及生存質量的影響. 中華普外科手術學雜志: 電子版, 2019, 13(2): 144-147.
22.	鄭權, 李曉鋒, 劉蓋, 等. 結直腸癌患者 ERAS 方案和術后住院時間的相關性分析. 嶺南現代臨床外科, 2019, 19(2): 130-134, 138.
23.	陳凜. 有關腹腔鏡胃癌根治術的若干問題. 中華胃腸外科雜志, 2005, 8(5): 396-397.
24.	Reisinger KW, Schellekens DH, Bosmans JW, et al. Cyclooxygenase-2 is essential for colorectal anastomotic healing. Ann Surg, 2017, 265(3): 547-554.
25.	劉琳. 加速康復外科策略中使用帕瑞昔布鈉對胃癌根治術后疼痛和早期恢復的影響. 合肥: 安徽醫科大學, 2018.

1. 陳學燕, 李利亞. 多原發惡性腫瘤臨床特點及發病機制的研究進展. 中日友好醫院學報, 2019, 33(1): 41-44.
2. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst, 2007, 99(21): 1634-1643.
3. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
4. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet, 2013, 50(4): 255-263.
5. Molina-Montes E, Requena M, Sánchez-Cantalejo E, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol, 2015, 136(1): 158-171.
6. Lenters-Westra E, Slingerland RJ. Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria. Clin Chem, 2014, 60(8): 1062-1072.
7. Braisch U, Meyer M, Radespiel-Tr?ger M. Risk of tobacco-related multiple primary cancers in Bavaria, Germany. BMC Cancer, 2012, 12: 250.
8. 奧婷, 孫軍平, 張明月, 等. 肺癌合并其他原發惡性腫瘤 55 例發病特點分析. 解放軍醫學院學報, 2016, 37(3): 226-228, 241.
9. Utada M, Ohno Y, Hori M, et al. Incidence of multiple primary cancers and interval between first and second primary cancers. Cancer Sci, 2014, 105(7): 890-896.
10. 宋詩平, 趙越, 王春玉. 雌激素受體在甲狀腺癌中作用的研究進展. 生命科學, 2017, 29(5): 489-494.
11. Noguchi M, Naruki Y, Matsuo K, et al. A case report of triple malignant tumor including early gastric carcinoma–multiple primary malignant tumors, a survey of the literatures and a statistical study (author’s transl). Nihon Shokakibyo Gakkai Zasshi, 1978, 75(1): 71-79.
12. Jin B, Zhang S, Chuang X, et al. Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report. BMC Cancer, 2018, 18(1): 1138.
13. 蘭春斌, 賈貴清, 袁浩, 等. 新輔助化療聯合完全腹腔鏡下遠端胃癌 D2 根治術的臨床療效. 中國臨床研究, 2019, 32(6): 747-750, 754.
14. Shoji F, Yamazaki K, Miura N, et al. Postoperative management of multiple primary cancers associated with non-small cell lung cancer. Anticancer Res, 2018, 38(6): 3773-3778.
15. Baba Y, Yoshida N, Kinoshita K, et al. Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: a retrospective single-institution study. Ann Surg, 2018, 267(3): 478-483.
16. 郭銳, 李囡, 王菲, 等. ¹⁸F-FDG PET/CT 在同時性多原發癌中的應用. 腫瘤, 2018, 38(4): 371-378.
17. 徐玲玲, 顧康生. 170 例多原發惡性腫瘤的臨床分析. 安徽醫科大學學報, 2011, 46(12): 1318-1321.
18. 端木媛媛, 王瑞平. 王瑞平教授治療多原發癌的經驗. 中醫藥導報, 2018, 24(9): 53-54, 65.
19. 孫俊杰, 李雙慶. 多原發癌病因及發病機制的探索. 中國全科醫學, 2017, 20(9): 1136-1141.
20. Gustafsson UO, Scott MJ, Schwenk W, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(?)) Society recommendations. World J Surg, 2013, 37(2): 259-284.
21. 韓偉峰, 費伯健, 高其忠, 等. ERAS 用于進展期胃癌 D2 根治術對胃腸功能恢復情況及生存質量的影響. 中華普外科手術學雜志: 電子版, 2019, 13(2): 144-147.
22. 鄭權, 李曉鋒, 劉蓋, 等. 結直腸癌患者 ERAS 方案和術后住院時間的相關性分析. 嶺南現代臨床外科, 2019, 19(2): 130-134, 138.
23. 陳凜. 有關腹腔鏡胃癌根治術的若干問題. 中華胃腸外科雜志, 2005, 8(5): 396-397.
24. Reisinger KW, Schellekens DH, Bosmans JW, et al. Cyclooxygenase-2 is essential for colorectal anastomotic healing. Ann Surg, 2017, 265(3): 547-554.
25. 劉琳. 加速康復外科策略中使用帕瑞昔布鈉對胃癌根治術后疼痛和早期恢復的影響. 合肥: 安徽醫科大學, 2018.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Minimally invasive laparoscopic treatment for gastric cancer with sigmoid colon cancer: a report of 1 case

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content